The scale of the unmet need is difficult to overstate. Idiopathic pulmonary fibrosis, or IPF, is a chronic, progressive interstitial lung disorder that is ultimately lethal, and the treatment options available today are very limited. The two approved anti-fibrotic drugs can only halt disease progression; they cannot reverse fibrotic tissue damage that has already been established. Once the lung architecture is remodeled by dense scar tissue, the loss of function is effectively permanent, and many patients eventually require a lung transplant to survive. This stark therapeutic ceiling is why researchers have increasingly turned their attention to the fundamental molecular machinery inside lung cells, searching for points of intervention that go beyond merely slowing the disease down.

One of the most intriguing classes of molecules to emerge from that search is the long non-coding RNAs, or lncRNAs. These are RNA transcripts that are copied from the genome but, unlike messenger RNAs, are not translated into proteins. For decades they were dismissed as genetic noise, but it is now clear that many of them act as sophisticated regulators of cellular behavior, influencing which genes are switched on or off and how cells respond to external signals. In fibrotic diseases, lncRNAs have appeared as important regulators of the scarring process. Yet the specific role of one prominent lncRNA, H19, in IPF remained incompletely understood, and it was this gap in knowledge that the new study set out to fill.

The researchers began with a straightforward but crucial observation: H19 is significantly upregulated in lung tissues from patients with IPF, in fibroblasts derived from those patients, and in human lung fibroblasts that have been activated in the laboratory by transforming growth factor beta 1, or TGF-β1, the master pro-fibrotic cytokine. Fibroblasts are the connective tissue cells of the lung, and in IPF they undergo a dramatic transformation into myofibroblasts, contractile cells that churn out collagen and other extracellular matrix proteins, stiffening the lung like scar tissue in a healing wound that never stops healing. The fact that H19 levels rise consistently in patient tissue and in experimentally activated fibroblasts suggested that the molecule is not a bystander but an active participant in this transformation.

To understand how H19 exerts its influence, the team dug into the molecule’s mechanism of action, and what they found is a textbook example of a regulatory strategy known as the competing endogenous RNA model, or ceRNA. In this model, a long non-coding RNA acts as a molecular sponge, soaking up and sequestering microRNAs, which are tiny RNA fragments that normally suppress gene expression by binding to target messenger RNAs. The researchers demonstrated that H19 specifically sequesters a microRNA called miR-103a-3p. Under normal circumstances, miR-103a-3p binds to and inhibits a bona fide target gene called TRIOBP, keeping the production of the TRIOBP protein in check. But when H19 is abundant, it mops up the microRNA, relieving that inhibitory effect and allowing TRIOBP levels to climb.

The consequences of that climb are profound. The study shows that the upregulation of TRIOBP triggers the PI3K/AKT signaling pathway, a well-known intracellular cascade that functions as a central control hub for cell survival, growth and metabolism. Once activated, this pathway facilitates the conversion of fibroblasts into myofibroblasts, the defining cellular event of pulmonary fibrosis. It also enhances the proliferative and migratory capacities of these cells, allowing them to multiply and spread through the lung tissue, and it confers resistance to programmed cell death, meaning the scar-forming cells survive when they should be eliminated. In effect, the H19/miR-103a-3p/TRIOBP axis rewires fibroblasts into persistent, invasive, scar-producing machines, all funneled through the activation of PI3K/AKT.

Crucially, the team did not merely correlate these molecular changes with disease; they perturbed them directly and watched what happened. When the researchers knocked down H19, or when they overexpressed miR-103a-3p to compensate for the sponge effect, the fibrotic phenotypes were attenuated: the fibroblasts became less myofibroblast-like, less proliferative, less migratory and less resistant to cell death. Conversely, when the researchers inhibited miR-103a-3p, they reversed the anti-fibrotic effect of H19 silencing, restoring the pro-fibrotic behavior of the cells. This series of gain-of-function and loss-of-function experiments establishes a clear causal chain rather than a mere association, and it demonstrates that the pro-fibrotic effects of H19 are mediated primarily through the sequestration of miR-103a-3p and the consequent activation of TRIOBP and the PI3K/AKT cascade.

The elegance of the ceRNA mechanism also carries practical implications for drug development. Traditional drugs target proteins, but the molecules in this pathway, H19 and miR-103a-3p, are RNAs, and the past decade has seen remarkable progress in RNA-based therapeutics, from antisense oligonucleotides to small interfering RNAs that can be designed to silence specific transcripts. A therapy aimed at reducing H19, or at delivering synthetic miR-103a-3p to restore the suppressed brake on TRIOBP, would operate at a level of the disease process that current anti-fibrotic drugs do not touch. The authors suggest that therapeutic intervention aimed at this pathway could offer a promising strategy for IPF, and the fact that the axis promotes proliferation, migration and survival resistance simultaneously means that blocking it could attack the disease from several directions at once.

There are, of course, important caveats and steps that remain before such a strategy could reach patients. The study was supported by the National Natural Science Foundation of China and several regional Chinese research programs, and the human specimens used were obtained with ethical approval from the First Affiliated Hospital of Zhengzhou University, with informed consent from all participants. Translating the findings into a clinical intervention will require demonstrating that the H19/miR-103a-3p/TRIOBP axis can be safely modulated in living lungs, that delivering RNA-targeted drugs to fibrotic lung tissue is feasible, and that suppressing the pathway does not interfere with normal wound healing elsewhere in the body. The PI3K/AKT pathway, in particular, is used by many cell types for many purposes, so any therapeutic approach will need to be carefully calibrated to avoid broad systemic effects.

Even so, the study represents a meaningful advance in understanding why the lungs of IPF patients keep scarring long after an injury has passed. By delineating the H19/miR-103a-3p/TRIOBP signaling axis as a pivotal promoter of fibrotic processes in the lung, the researchers have converted a mysterious regulatory RNA into a concrete, mechanistically defined link in the chain that leads from activated fibroblast to lethal pulmonary scar. For a disease in which existing drugs can only slow the clock, the identification of a druggable circuit that sits upstream of myofibroblast transformation, proliferation, migration and survival offers something genuinely new: a molecular explanation of the disease’s persistence, and a plausible route toward therapies that might one day do more than merely delay the inevitable.

Subject of Research: The role of the lncRNA H19/miR-103a-3p/TRIOBP axis in activating PI3K/AKT signaling and driving fibroblast-to-myofibroblast transformation in idiopathic pulmonary fibrosis

Article Title: H19 promotes the development of idiopathic pulmonary fibrosis by modulating TRIOBP to stimulate the PI3K/AKT signaling pathway

Article References: Zhao, W.-Y., Zhao, H., Yang, T., Huang, S., Chen, Y., Li, Z., Leask, A., Kim, G.-Y., Song, J., Yu, G., & Wang, L. (2026). H19 promotes the development of idiopathic pulmonary fibrosis by modulating TRIOBP to stimulate the PI3K/AKT signaling pathway. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06444-2

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06444-2

Keywords: idiopathic pulmonary fibrosis, long non-coding RNA, H19, miR-103a-3p, TRIOBP, PI3K/AKT signaling, competing endogenous RNA, myofibroblast, TGF-beta 1, lung fibrosis, RNA therapeutics, fibroblast activation

Extracellular vesicles, or EVs, were once dismissed as cellular debris, but researchers now recognize them as a fundamental communication system. Every cell type in the lung releases them, and their cargo is not random. A vesicle shed by an injured alveolar epithelial cell carries a molecular snapshot of that cell’s stress state, and when it fuses with a fibroblast deep in the interstitium, it can reprogram the recipient’s behavior. The review synthesizes evidence that this vesicle-mediated crosstalk sits at the heart of the fibrotic cascade, driving the transformation of quiescent fibroblasts into collagen-producing myofibroblasts and fueling the relentless accumulation of scar tissue.

The most detailed mechanistic story involves microRNAs, short non-coding RNA molecules that silence target genes after delivery into recipient cells. Epithelial- and immune-cell-derived vesicles can carry pro-fibrotic microRNAs such as miR-494-3p, which converge on the transforming growth factor beta (TGF-β)/Smad pathway and the Wnt/β-catenin pathway, the two canonical signaling axes that orchestrate fibroblast-to-myofibroblast transition. Other studies cited in the review show that senescent epithelial cells release vesicles containing miR-217-5p, which suppresses the Sirt1 axis in fibroblasts, while endothelial cells depleted of let-7d emit vesicles that push pericytes toward a fibrotic fate through the TGFβRI/FoxM1/Smad/β-catenin route. In each case, the vesicle is not merely a bystander but an active vector of disease transmission.

The review also describes a self-amplifying quality to this system that helps explain why pulmonary fibrosis, once established, tends to accelerate. Fibroblast-derived vesicles carrying the secreted protein SFRP1 can induce senescence in epithelial cells, and myofibroblast-derived vesicles operating through a Nestin-Rab7 axis appear to propagate profibrotic signals in a cascade. Macrophages add another layer: pyroptotic macrophages release vesicles whose microRNA cargo drives fibroblast-to-myofibroblast transition in silica-induced models, and macrophage-derived exosomal HMGB3 promotes M1 polarization and recruitment of inflammatory cells. In effect, the disease creates its own messengers, and each round of vesicle exchange deepens the fibrotic loop.

What makes the field genuinely exciting, however, is that the same delivery system can be turned against the disease. Mesenchymal stem cell-derived extracellular vesicles, or MSC-EVs, have shown consistent anti-fibrotic effects in preclinical models. Umbilical cord MSC-EVs attenuate fibrosis by inhibiting TGF-β signaling, and specific microRNA cargoes have been pinned to discrete mechanisms: miR-186 interacting with SOX4 and DKK1, miR-29c and miR-129 transferred between cells to facilitate resolution of fibrosis, miR-31-5p repressing fibrosis via IGFBP7, miR-4516 suppressing integrin αV-mediated fibrosis, and miR-148a-3p inhibiting β-catenin signaling in silica-induced disease. MSC-EVs also modulate immune responses, shifting macrophages toward the pro-resolving M2 phenotype, curbing monocyte-macrophage migration through ERK1/2-mediated suppression of CCL2, and restoring mitochondrial function and autophagy in damaged epithelium.

The translational pipeline has already produced a milestone. A phase I clinical investigation of nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis has provided initial evidence that inhaled, clinical-grade vesicle preparations can be administered safely. The review is careful to note that therapeutic efficacy in pulmonary fibrosis has not yet been established, but the safety signal, together with earlier preclinical work on nebulized allogenic adipose MSC-derived vesicles, establishes a plausible route of administration that delivers vesicles directly to the lung while avoiding much of the systemic exposure that complicates cell-based therapies.

Beyond MSC-EVs, the review surveys an emerging menagerie of alternative vesicle platforms. Plant-derived exosome-like nanoparticles from fruits, vegetables and herbs, including broccoli and grapefruit preparations, have demonstrated anti-inflammatory and drug-carrier properties, and plant-derived exosomal microRNAs have been shown to inhibit lung inflammation triggered by SARS-CoV-2 protein-containing vesicles. Milk-derived vesicles are particularly attractive for inhalation therapy because they are abundant, scalable and generally regarded as safe; nebulized milk exosomes loaded with siRNA against TGF-β1 have ameliorated pulmonary fibrosis in animal models, and milk-derived vesicles loaded with glycyrrhetinic acid have been developed for inhalation treatment of idiopathic pulmonary fibrosis. Engineered macrophage-derived exosomes have even been used to deliver pirfenidone directly to fibrotic lung tissue in silicosis models, combining an existing drug with targeted vesicle delivery.

Parallel to the therapeutic story runs a diagnostic one. Because vesicles cross into nearly every body fluid and carry disease-specific cargo, they are attractive candidates for liquid biopsy. The review compiles evidence that EVs isolated from plasma, bronchoalveolar lavage fluid, sputum and urine carry molecular signatures associated with pulmonary fibrosis. Serum vesicle biomarkers have been reported to reflect disease activity in idiopathic pulmonary fibrosis, and SFTPB protein in serum extracellular vesicles has been proposed as a marker of progressive pulmonary fibrosis. Distinct exosomal microRNA profiles distinguish BAL fluid from patients with idiopathic pulmonary fibrosis and COPD, sputum exosomes have been flagged as promising biomarkers for IPF, and urine-derived exosomes from IPF patients carry pro-fibrotic cargo. Downregulation of exosomal let-7d and miR-16 has been documented in IPF patients, and exosomal miR-143-5p and miR-342-5p regulate fatty acid synthase in the disease. If validated, such signatures could allow earlier diagnosis and non-invasive monitoring of a disease that is currently confirmed only through a combination of high-resolution computed tomography and, in uncertain cases, surgical lung biopsy.

The authors are candid about the obstacles standing between this science and the clinic. Vesicle cargo varies with the source cell, culture conditions and isolation method, and the field’s reporting standards, codified in frameworks such as MISEV2023, are still being adopted unevenly. Cargo standardization, targeted delivery to fibrotic regions of the lung, and scalable manufacturing remain unsolved problems; a single therapeutic dose may require vesicle quantities that current production pipelines struggle to supply. Recent work on scalable platforms for induced pluripotent stem cell-derived MSC vesicles and on three-dimensional culture systems that enhance vesicle potency suggests these bottlenecks are not insurmountable, but clinical adoption will demand rigorous batch-to-batch consistency and regulatory frameworks that barely exist today.

Still, the conceptual shift the review describes is hard to overstate. Pulmonary fibrosis has long been treated as a disease of runaway cells, attacked with broad drugs that dampen proliferation and inflammation without addressing why the fibrotic program persists. The extracellular vesicle perspective reframes the disease as a communication failure, in which injured cells broadcast profibrotic instructions and healthy counter-signals are drowned out. Restoring the balance, whether by blocking harmful vesicle cargo, delivering anti-fibrotic microRNAs in engineered vesicles, or reading vesicle signatures to catch the disease before it becomes irreversible, offers a strategy that is mechanistically precise in a way current therapies are not. For patients whose lungs are steadily stiffening despite the best available drugs, that reframing may prove to be the most important development in the field in two decades.

Subject of Research: The role of extracellular vesicles and microRNAs in pulmonary fibrosis pathogenesis, diagnosis, and therapy

Article Title: How extracellular vesicles contribute to pulmonary fibrosis: miRNA-mediated mechanisms, diagnostic potential, and emerging therapeutic strategies

Article References: Liu, X., Zhao, Z., Zhu, L., Zhang, W., Zhou, J., Wu, X., & Jiang, L. (2026). How extracellular vesicles contribute to pulmonary fibrosis: miRNA-mediated mechanisms, diagnostic potential, and emerging therapeutic strategies. Molecular Biology Reports, 53(1), Article 1672. https://doi.org/10.1007/s11033-026-12858-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12858-9

Keywords: pulmonary fibrosis, extracellular vesicles, exosomes, microRNAs, TGF-beta signaling, mesenchymal stem cells, biomarkers, drug delivery, idiopathic pulmonary fibrosis, myofibroblast, MSC-EVs, nebulized therapy

The chemical modification at the heart of the study is N6-methyladenosine, abbreviated m6A, the most abundant internal modification found in messenger RNA. In this process, a methyl group is attached to the nitrogen at position six of adenosine bases, a change that can alter how efficiently a transcript is translated, where it localizes, and, crucially, how long it survives before being degraded by the cell’s RNA-decay machinery. METTL3 is the catalytic core of the methyltransferase complex that writes these marks. Because m6A methylation has already been implicated in cancer, cardiovascular disease, and a range of fibrotic disorders, and because previous work showed that silencing METTL3 blocks the conversion of fibroblasts into scar-forming myofibroblasts, the team reasoned that the enzyme might also govern the lipid disturbances that increasingly appear central to pulmonary fibrosis.

That lipid connection is not incidental. Lipids serve not only as structural components of cellular membranes but also as signalling molecules that modulate fibroblast activation and extracellular matrix production, and dysregulated lipid metabolism has emerged as a critical factor in the pathogenesis of idiopathic pulmonary fibrosis. The protein PLIN2, a member of the perilipin family, coats the surface of intracellular lipid droplets and acts as a gatekeeper, controlling the entry of lipases and their cofactors into the stored lipids and thereby regulating lipolysis. PLIN2 has been linked to myocardial infarction, obesity, fatty liver disease, and lipogenic differentiation in lung fibrosis, but its relationship with METTL3 had never been explored.

To establish the disease context, the researchers used the well-characterized bleomycin model, in which the chemotherapy drug bleomycin is delivered directly into the airways of mice to provoke fibrotic injury that resembles the human condition. Histological examination with haematoxylin and eosin and Masson’s trichrome staining confirmed that bleomycin destroyed normal lung architecture and drove collagen deposition. Molecular assays showed elevated levels of the fibrosis markers collagen I and alpha-smooth muscle actin, while Nile Red fluorescence staining of lung sections revealed a marked increase in lipid deposition. Critically, METTL3 expression was significantly upregulated in the fibrotic lungs. The same pattern appeared in vitro: WI-38 human embryonic lung fibroblasts treated with transforming growth factor beta 1, a standard mimic of the fibrotic environment, also raised their METTL3 levels.

The team then asked what happens when METTL3 is removed. Using short hairpin RNA to knock down the enzyme in TGF-beta1-treated WI-38 cells, they observed a broad calming of the fibrotic program. Expression of lipogenesis markers including fatty acid synthase, acetyl-CoA carboxylase 1, SREBP1, and PPARalpha, all of which had been elevated by TGF-beta1, fell back toward baseline. Collagen I and alpha-smooth muscle actin declined at both the messenger RNA and protein levels, a result confirmed by immunofluorescence imaging of alpha-smooth muscle actin. Oil Red O staining showed that the abundance of lipid droplets induced by TGF-beta1 was partly abolished when METTL3 was silenced, demonstrating that the enzyme’s influence extends from scar formation to fat handling within the same cells.

The mechanistic core of the paper lies in what METTL3 does to PLIN2. When the researchers silenced METTL3, PLIN2 expression rose. Methylated RNA immunoprecipitation showed that the m6A levels on PLIN2 transcripts dropped in parallel, and RNA immunoprecipitation confirmed a direct physical interaction between METTL3 and the PLIN2 RNA. Using the SRAMP prediction database, the team identified five candidate methylation sites, selected the three with the highest confidence, and tested them individually with a dual-luciferase reporter assay in which the wild-type or site-mutated PLIN2 sequence was inserted downstream of a luciferase gene. Silencing METTL3 increased reporter activity only for the construct containing site 2, pinpointing that single adenosine as the functionally relevant methylation site. Actinomycin D chase experiments, which block new RNA synthesis and allow existing transcripts to decay, showed that METTL3 knockdown significantly prolonged PLIN2 messenger RNA half-life, confirming that the enzyme normally destabilizes the transcript through m6A-dependent decay.

To prove that PLIN2 is not merely a bystander but the functional downstream effector, the researchers performed an epistasis experiment. When they knocked down PLIN2 in cells in which METTL3 had already been silenced, the protective effects of METTL3 loss were reversed. The suppression of lipogenesis markers was abrogated, collagen I and alpha-smooth muscle actin climbed back up, and the reduction in lipid droplets was counteracted. In other words, removing PLIN2 restored the fibrotic and lipid-accumulating phenotype even in the absence of METTL3, placing PLIN2 squarely downstream of the methyltransferase in the pathway that connects RNA methylation to scar formation.

The in vivo experiments reinforced the story. Twenty mice per group were randomly assigned to control, bleomycin, bleomycin plus a control short hairpin RNA, or bleomycin plus shMETTL3 delivered intratracheally by adenovirus. Over 28 days, bleomycin reduced survival, while METTL3 knockdown improved it. Histology showed that silencing METTL3 impeded the destruction of lung structure and the deposition of collagen fibres. Nile Red staining demonstrated that the lipid accumulation driven by bleomycin was counteracted by METTL3 knockdown, and the elevated collagen I and alpha-smooth muscle actin levels in fibrotic lungs fell after METTL3 interference. Immunohistochemistry revealed that PLIN2, which was downregulated in the bleomycin model, was restored by METTL3 silencing, mirroring the cellular findings and tying improved survival and tissue architecture to the restored lipid-droplet protein.

The findings fit into a growing body of work implicating m6A machinery in fibrotic disease across organs. METTL3 knockdown has been reported to inhibit fibroblast proliferation and migration in cardiac fibrosis, to ameliorate kidney fibrosis by reducing fibrotic marker expression, and to promote macrophage pyroptosis that aggravates liver fibrosis. In the lung specifically, METTL3-mediated methylation has been shown to drive fibroblast differentiation into myofibroblasts through the miR-21/PTEN pathway, and m6A-modified circular RNAs have been linked to ferroptosis in pulmonary fibrosis. The new study extends this landscape by identifying PLIN2 as a novel methylation substrate and by connecting RNA epigenetics directly to lipid metabolism, a dimension of pulmonary fibrosis biology that involves lipofibroblast activation, lung remodelling, and pathways such as lysophosphatidic acid signalling.

The authors are careful to note the limitations of their work. WI-38 embryonic fibroblasts, while genetically stable and widely used to study the fibroblast-to-myofibroblast transition, cannot fully recapitulate the pathology of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis, and embryonic cells may differ from adult disease fibroblasts in epigenetic and lipid metabolic profiles, so validation in MRC-5 cells or primary patient fibroblasts will be needed. The team validated a single methylation site by reporter assay but did not perform transcriptome-wide m6A mapping such as MeRIP-seq or miCLIP to exclude additional sites, and the role of PLIN2 in vivo requires further preclinical testing. Even so, the central conclusion stands: METTL3 promotes lipid deposition and fibrosis by destabilizing PLIN2 messenger RNA in an m6A-dependent manner, and interventions that raise PLIN2 expression, whether directly or by silencing METTL3, offer a conceptually new route to treating a disease that urgently needs one.

Subject of Research: The role of METTL3-mediated m6A modification of PLIN2 in lipid metabolism and pulmonary fibrosis

Article Title: METTL3 Promotes Lipid Deposition and Pulmonary Fibrosis by Destabilizing PLIN2 in a m6A‐Dependent Manner

Article References: Liu, Q., Xu, R., & Du, X. (2026). METTL3 Promotes Lipid Deposition and Pulmonary Fibrosis by Destabilizing PLIN2 in a m6A‐Dependent Manner. Journal of Cellular and Molecular Medicine, 30(17), Article e71239. https://doi.org/10.1111/jcmm.71239

Image Credits: AI Generated

DOI: 10.1111/jcmm.71239

Keywords: idiopathic pulmonary fibrosis, METTL3, m6A methylation, PLIN2, lipid metabolism, RNA modification, pulmonary fibrosis, fibroblasts, myofibroblast, bleomycin model, epitranscriptomics, TGF-beta1

Alveolar echinococcosis is rare but devastating. The parasite’s larvae proliferate in the liver in a tumor-like fashion, provoking granulomatous inflammation and driving progressive scarring of the surrounding tissue. Clinicians have long observed that patients with advanced disease show suppressed immune activity and extensive fibrosis, but the cellular choreography that carries the liver from acute inflammation to chronic remodelling has remained poorly defined. The central problem, the authors note, is spatial: immune cells do not act in isolation but within structured niches, and conventional bulk methods dissolve that architecture into averages. The new study set out to preserve the geography.

The team used an experimental model in which mice received a secondary hepatic infection with E. multilocularis protoscoleces, the larval forms that initiate disease. Liver tissue was collected from uninfected animals and from mice at two timepoints: two weeks after infection, representing the early inflammatory phase, and three months after infection, representing the chronic phase. Four complementary techniques were layered on top of one another: flow cytometry to quantify immune populations, immunofluorescence microscopy to place specific markers in tissue, single-cell RNA sequencing to profile individual cells, and Visium HD spatial transcriptomics to map gene expression across intact liver sections at high resolution.

The flow cytometry results traced the arc of the immune response with striking clarity. Two weeks after infection, eosinophils, macrophages, and CD4-positive T cells surged in the infected livers, a signature of vigorous anti-parasitic mobilization. By three months, these populations had declined, yet eosinophils and macrophages remained elevated above levels seen in uninfected control animals, hinting that the immune system never fully stands down even as the disease settles into its chronic state. This partial, persistent activation is a key piece of the puzzle of how alveolar echinococcosis smolders for years, sometimes decades, in human patients.

The single-cell and spatial data then revealed what those flowing populations were actually doing. At the two-week mark, distinct stromal cell subsets had already infiltrated the granulomatous areas that form around parasite tissue. Among them were three transcriptionally distinct populations of endothelial cells, labeled ECs1, ECs2, and ECs3, alongside a marked accumulation of myofibroblasts, the contractile, matrix-producing cells best known for driving wound healing and fibrosis. By the chronic three-month phase, those myofibroblasts had significantly ramped up expression of Timp1 and Spp1, two well-established pro-fibrotic markers, indicating that the parasite-associated lesions had become active engines of scar formation.

The myeloid compartment proved equally heterogeneous. Monocyte-derived macrophages diversified into two recognizable subtypes, one characterized by Arg1 and Spp1 expression and another marked by Ccr7 and Itgax, profiles associated respectively with tissue remodeling and inflammatory activation. Meanwhile, Kupffer cells, the liver’s resident macrophages, showed a different trajectory: during chronic infection, their expression of inflammatory cytokines fell significantly. The juxtaposition of pro-inflammatory monocyte-derived cells with quieted resident macrophages suggests that the parasite-associated environment reshapes the myeloid landscape in ways that may blunt effective anti-parasitic immunity while promoting tissue damage and repair gone awry.

Perhaps the most intriguing finding concerned eosinophils, the granulocytes typically associated with anti-parasitic defense and allergic disease. In this model, eosinophils were specifically enriched in the cores of hepatic granulomas two weeks after infection. But their gene expression profile was not purely inflammatory. Instead, they displayed an immunoregulatory transcriptional program, and the spatial maps placed them in close proximity to cells expressing IL-33, an alarmin cytokine with well-documented roles in type 2 immunity and tissue repair. The colocalization raises the possibility that granuloma-core eosinophils are not simply attacking the parasite but actively sculpting a tolerance-promoting microenvironment, a hypothesis the authors suggest merits direct testing in future studies.

T cells told a complementary story about geographic segregation. CD8-positive T cells split into two functionally distinct subsets: an Ifng-expressing effector population, capable of the antiviral and antiparasitic cytotoxicity associated with interferon-gamma, and a Gzmk-positive subset bearing migratory and homeostatic characteristics. Notably, both populations were found predominantly outside the granulomatous areas, in the surrounding non-granulomatous liver. The cytotoxic arm of adaptive immunity, in other words, appears to be kept at the perimeter of the parasite-associated lesions, potentially unable to reach the parasite itself, which sits protected at the granuloma’s center.

By combining spatial deconvolution, a computational technique that estimates which cell types occupy each spot on a tissue map, with cell-cell communication analysis, the team identified the collagen-rich granuloma as a critical signaling niche. Their predictions pointed to myofibroblast-derived collagen signals, exemplified by the COL1A1–CD44 ligand-receptor pair, interfacing with lymphocytes at the granuloma boundary. This offers a concrete molecular hypothesis for how fibrotic stromal cells communicate with immune cells and potentially enforce the immunosuppressive character of chronic alveolar echinococcosis. Collagen-rich matrices are known to physically impede T cell migration in cancer, and the parallel here is difficult to ignore.

The authors frame the work as a spatially resolved cellular framework for understanding the immune-stromal regulatory network during E. multilocularis infection, and as a foundation for future studies of disease pathogenesis. The implications reach beyond parasitology. If myofibroblasts are confirmed as central architects of both fibrosis and immune suppression in alveolar echinococcosis, they become candidate targets for adjunctive therapies aimed at slowing disease progression, complementing the surgery and benzimidazole chemotherapy that form today’s standard of care. With the collaboration between advanced single-cell technology and high-resolution spatial mapping now demonstrated in this infection model, the field has, for the first time, a genuine atlas of the terrain on which this devastating parasite reshapes its host.

Subject of Research: Immune–stromal cell interactions in Echinococcus multilocularis metacestode infection mapped by single-cell and spatial transcriptomics

Article Title: Integrating single-cell RNA sequencing with Visium HD spatial atlas reveals immune–stromal cell interactions in Echinococcus multilocularis metacestode infection

Article References: Yan, M., Qi, W., Zhang, G., Wang, X., Wu, C., Tian, M., Geng, A., Wang, H., Zhang, C., Li, J., & Zhang, W. (2026). Integrating single-cell RNA sequencing with Visium HD spatial atlas reveals immune–stromal cell interactions in Echinococcus multilocularis metacestode infection. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07591-y

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07591-y

Keywords: alveolar echinococcosis, Echinococcus multilocularis, single-cell RNA sequencing, spatial transcriptomics, Visium HD, myofibroblast, granuloma, liver fibrosis, eosinophils, macrophages, immune evasion, parasitic liver disease

Cardiac fibrosis is the pathological accumulation of extracellular matrix proteins in the heart, a process orchestrated primarily by fibroblasts. When the heart is stressed by pressure overload, myocardial infarction, or chronic inflammation, quiescent fibroblasts activate into myofibroblasts, cells that proliferate, migrate, contract, and deposit large quantities of collagen and other matrix components. In the short term this response is protective, patching damaged tissue and preserving the structural integrity of the ventricular wall. When the signal never shuts off, however, the accumulating scar stiffens the myocardium, impairs electrical conduction, and gradually pushes the heart toward diastolic dysfunction and heart failure. Clinically, no approved therapy directly targets this process; existing treatments manage hemodynamic load and neurohormonal activation while fibrosis progresses.

PTBP1, polypyrimidine tract binding protein 1, is one of the cell’s most influential splicing factors. Alternative splicing allows a single gene to yield multiple protein isoforms by including or excluding different RNA segments, and PTBP1 binds specific sequence motifs on precursor messenger RNA to tip these decisions. Beyond splicing, PTBP1 participates in RNA stability, translation, and even transcript localization, and it is famous in regenerative biology for its ability, when silenced, to help convert non-neuronal cells into neuron-like cells. Its role in the heart’s fibrotic armory, however, has been far less clear, and the new study set out to test whether fibroblast PTBP1 is a bystander or an active participant in scarring.

To resolve that question, the investigators generated mice in which PTBP1 was deleted selectively in cardiac fibroblasts, sidestepping the developmental and neuronal roles of the protein that complicate whole-animal knockout approaches. This cell-type-specific strategy is essential because PTBP1 is broadly expressed; removing it everywhere would produce a tangle of secondary effects impossible to attribute to fibroblasts. With the deletion restricted to the scar-forming population, the researchers could ask a clean question: when fibroblasts lose their master splicing regulator, does the fibrotic response to cardiac stress change, and if so, how?

The answer was yes, and the mechanism was legible at the level of the transcriptome. Fibroblasts lacking PTBP1 showed broad alterations in alternative splicing, and among the affected transcripts were genes central to the profibrotic program. The splice isoforms produced in the knockout cells differed from those made in wild-type fibroblasts in ways that modulated the cells’ sensitivity to the cytokine TGF-beta, the dominant driver of myofibroblast differentiation, and to the downstream signaling that activates collagen production and contractility. In effect, removing the splicing factor rewired the interpretive layer between the fibrotic signals a cell receives and the proteins it deploys in response.

This outcome matters conceptually because much of fibrosis research has concentrated on transcriptional control, asking which transcription factors activate fibrotic genes and which signaling cascades converge on their promoters. The PTBP1 data demonstrate that post-transcriptional regulation constitutes a second, largely independent control layer. A gene can be transcribed at a normal rate yet produce a protein with altered function if its exons are assembled differently. In fibroblasts, that assembly step is influenced heavily by PTBP1, meaning the intensity and character of the scarring response can be tuned without changing gene expression in the conventional sense.

Technically, the study illustrates the current standard toolkit for dissecting splicing in vivo. RNA sequencing of fibroblasts isolated from control and knockout animals allowed the team to quantify splicing changes genome-wide, identifying skipped exons, alternative splice sites, and shifted isoform ratios across thousands of transcripts. These molecular maps were then connected to cellular phenotypes measured in culture and to the intact organ in models of cardiac stress, an approach that links a molecular event, exon usage, all the way through to tissue-level consequences. It is exactly this chain of evidence, from factor to isoform to cell behavior to organ pathology, that turns a correlation into a credible regulatory mechanism.

One of the most interesting implications concerns isoform switching as a therapeutic concept. If individual fibrotic genes exist in profibrotic and less-pathological isoforms, then future interventions might not need to silence a gene outright, which is often toxic because genes rarely have a single role. Instead, drugs could be designed to nudge splicing decisions toward protective isoforms. Splice-switching oligonucleotides, short synthetic molecules that bind pre-mRNA and redirect the splicing machinery, are already approved for neuromuscular disease and are being explored in cardiology. A validated role for PTBP1 in the fibrotic response provides a concrete molecular handle for that class of strategy in heart disease.

The work also adds to a growing literature on RNA-binding proteins as disease genes. Over the past decade, RNA processing factors have been implicated in cardiomyopathy, congenital heart disease, and cardiac aging, but fibroblasts have received less attention than cardiomyocytes in this respect. Given that fibroblasts compose the majority of non-muscle cells in the heart and are the chief effectors of remodeling, the demonstration that a single splicing factor modulates their pathological activation suggests that the post-transcriptional biology of these cells is a rich and underexplored therapeutic landscape.

Important caveats remain. PTBP1 is a pleiotropic regulator, and changing its dosage in fibroblasts will inevitably affect many targets, some beneficial and some not; translating the finding into a therapy will require identifying the specific isoform switches that carry the antifibrotic effect and finding selective ways to control them. Dose, timing, and cell-type specificity will all need careful optimization, and the long-term consequences of altering fibroblast splicing in a chronically stressed heart are unknown. Nevertheless, the study delivers a clear and consequential message: the heart’s scarring response is governed not only by which profibrotic genes are expressed, but by how their RNA is edited, and a single RNA-binding protein helps call those shots. In a field where therapeutic options for fibrosis remain limited, that is a lead worth pursuing.

Subject of Research: Role of the splicing factor PTBP1 in cardiac fibroblast profibrotic activation and alternative splicing.

Article Title: Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing

Article References: Ricketts, S. N., Farber, G. M., Verma, S. K., Dong, Y., Xie, Y., Takasugi, P. R., Chen, S., Du, L., Wang, H., Hui, W., Keles, C., Tsoy, S., Fuller, G., Wang, M., Gentile, G. M., Giudice, J., Kuyumcu-Martinez, M. N., Liu, J., & Qian, L. (2026). Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing. Nature Communications. https://doi.org/10.1038/s41467-026-77609-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77609-7

Keywords: PTBP1, cardiac fibroblasts, alternative splicing, cardiac fibrosis, TGF-beta, RNA-binding protein, myofibroblast, heart failure, splicing factors, extracellular matrix, Cardiac, fibroblast